Vimian Retains Hold Rating as Solid Q1 Growth Offsets Margin Headwinds; SEK37 Price Target Reaffirmed

In a report released today, Adela Dashian from Jefferies maintained a Hold rating on Vimian Group AB, with a price target of SEK37.00.

Adela Dashian has given his Hold rating due to a combination of factors, including Vimian’s solid Q1 performance and remaining headwinds. The company delivered better‑than‑expected revenue and adjusted EBITA, with broad‑based organic growth across all divisions, which supports confidence in its underlying growth trajectory and justifies keeping the SEK37 price target unchanged.

At the same time, profitability trends are uneven, as margin gains in Specialty Pharma are partly offset by elevated investments in MedTech orthopedics, expansion initiatives in Veterinary Services, and an adverse mix effect in Diagnostics. This balance of strong top‑line momentum but constrained margin upside and ongoing investment needs leads Dashian to see limited near‑term rerating potential, supporting a Hold rather than a more aggressive rating despite the 31% implied upside to the target price.

According to TipRanks, Dashian is a 3-star analyst with an average return of 4.8% and a 40.95% success rate. Dashian covers the Industrials sector, focusing on stocks such as Munters Group AB, AFRY AB Class B, and Systemair AB.